An Epidemiological Study of Hemodialysis Patients Based on the European Fresenius Medical Care Hemodialysis Network: Results of the ARO Study
Ángel L.M. de Francisco, Pedro Aljama(Instituto Maimónides de Investigación Biomédica de Córdoba), Iain C. Macdougall(King's College Hospital), Bart Molemans(Amgen (United States)), Peter Stenvinkel(Karolinska Institutet), Guntram Schernthaner(Rudolfinerhaus Hospital), Bernard Canaud(Université de Montpellier), Bruno Fouqueray, Vasily Belozeroff(Amgen (United States)), Kai‐Uwe Eckardt(Friedrich-Alexander-Universität Erlangen-Nürnberg), David C. Wheeler(University College London), Florian Kronenberg(Innsbruck Medical University), Daniele Marcelli(Fresenius Medical Care (Germany)), Tilman B. Drüeke(Inserm), Joseph Kim(Amgen (United Kingdom)), Jürgen Floege(Westfälische Hochschule), Stefan D. Anker(Bayer (Germany)), Jutta Passlick‐Deetjen(Fresenius Medical Care (Germany)), Charles Chazot(Clinique Charcot)
Cited by 26
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k